Becker Transactions to broker non-thermal plasma deposition patent portfolio

Frederick R. Guy has named Becker Transactions as the exclusive representative for his non-thermal plasma deposition patent portfolio, which covers open-air material deposition at controlled temperatures, including applications on living tissue. The offering includes U.S. and European patents, a pending continuation, and is subject to a pre-existing field-limited manufacturing license.

Why it matters: - The portfolio targets a long-standing process gap: open-air deposition at temperatures low enough for fragile substrates, including tissue, without a vacuum chamber. - The claimed range could affect materials processing, restoration, and biomedical uses where heat or enclosure limits current plasma and deposition systems. - The portfolio is protected at least through 2035, giving potential buyers time to commercialize or license the technology.

What happened: - Frederick R. Guy announced that his non-thermal plasma deposition patent portfolio is being exclusively represented by Becker Transactions for acquisition or licensing. - Guy is an attorney, inventor, and former General Counsel of the U.S. Agency for International Development. - The technology was described as a patented process that deposits material onto a substrate in open air at a temperature tuned to the substrate. - The process can operate near ambient temperature at the low end and does not require a vacuum chamber.

The details: - The portfolio covers deposition of material onto a substrate by means of a non-thermal plasma stream. - A biocompatible carrier gas, which may be ambient air, is excited to form a plasma stream whose temperature is set for the application site. - The disclosure contemplates powders, solutions, aerosols, minerals, and polymerizable materials. - Plasma polymerization can occur at the application site. - The process is described as producing crystal growth in treated material and forming a structure that matches the crystalline structure of the application site. - Deposits are contemplated at structural thicknesses for restoration and surface coating. - A conformable hood coaxial with the deposition nozzle is designed to cover the target material and provide some vacuum-process benefits to a portable or robot-mounted head. - The technology is described as addressing two broad domains: materials processing and restoration. - Dental, orthopedic, tissue, and wound uses are described in the disclosure as examples of applications. - Becker Transactions said the technology expands the range of materials that can be deposited safely onto delicate substrates, including living tissue. - Dean Becker, chairman of Becker Transactions, said the portfolio could connect with stakeholders looking to transform their industries. - The offered portfolio includes U.S. Patent No. 10,384,069, U.S. Patent No. 11,642,542, and European Patent No. 3,417,827, validated in Germany, France, and the United Kingdom. - The package also includes continuations, divisionals, foreign counterparts, and a pending U.S. continuation application. - Guy is the sole named inventor and sole owner of record. - The assets are held personally and are not encumbered by any lien or security interest. - The offering is subject to a pre-existing, field-limited manufacturing license previously granted to Archion Biomaterials Company, Inc. and its subsidiary Dentivia LLC. - Certain related patents, including Guy's separate vegetable ivory biomaterial portfolio, are excluded from the offering.

Between the lines: - The pitch is not just about a new material-deposition method. It is about moving plasma processing out of the lab and into settings that need portability and lower heat. - The combination of open-air operation and temperature control is the main commercial hook because it removes two common barriers at once: heat damage and chamber size. - The presence of an existing manufacturing license means any buyer would need to plan around pre-existing rights.

What's next: - Becker Transactions will handle all inquiries about the portfolio. - Prospective acquirers or licensees will need to review the patent set, the pending continuation, and the disclosed field-limited license before moving forward. - The parties are positioning the technology for buyers in materials processing, restoration, and adjacent biomedical markets.